HPV DNA testing is more sensitive for detecting cervical lesions than cytology alone.
Findings provide, “overwhelming evidence of the benefits of inclusion of HPV testing in scaning programs.”
The Lancet Oncology reported a recent Population Based Screening study Amsterdam (POBASCAM) maned by Chris Meijer MD of VU University Medical Center in Amsterdam. The study screened women between the ages of 29-56 between Jan 1999 to Sept 2002 to either HPV DNA testing and cytology or to just cytology alone. The screening included a five year followup.
Researchers found that in the five year followup, they had fewer higher grade lesions and cervical cancers.
The study led to “earlier detection of clinically relevant [neoplasia] grade 2 or worse. ”